Maria Thacker Goethe headshot

Dear Members and Partners,

The Center for Global Health Innovation and Georgia Bio advocate for science, communities, and global health. We believe science must be at the forefront of COVID-19 response and all worldwide health issues.

We believe in science, and we believe in communities. For the businesses who call these communities ‘home,’ science and public health recommendations are more important than ever in helping business owners and essential workers combat COVID-19.

For these reasons, we have signed the Georgia Safety Promise , a statewide public-private partnership that encourages businesses and communities to agree to simple, but critical, measures that will keep communities safe. Our collective knowledge of science shows us that the measures outlined in the Safety Promise are the best way to combat COVID-19 and its impact on our state.

The health and safety of our member companies’ employees is top of mind. We are concerned that any increase in COVID-19 cases in Georgia could impact the important work that the biopharmaceutical and MedTech companies are doing. Georgia companies and institutions have enhanced research and manufacturing capabilities for vaccines and treatments for COVID-19. Our member companies are committed to continuing the important work they do in Georgia, which is critical to our collective success to ultimately have a vaccine and treatment for COVID-19.

We encourage our partners and members to join us in supporting science by signing the Safety Promise. Wearing face coverings, washing your hands, sanitizing surfaces, and staying six feet apart are scientifically proven to reduce transmission of this virus.

I would like to also bring to your attention a new national public health campaign designed to mobilize support for vaccines. The Public Good Projects (PGP) in partnership with BIO launched a national public health campaign called STRONGER —a first-of-its-kind effort designed to combat the spread of vaccine misinformation online.

STRONGER provides a guide for individuals to combat misinformation, explaining how to spot it, and then block, hide, report, or respond to false posts with facts and a list of trusted experts as a resource for good information on vaccines on social media.

For more information, visit www.stronger.org and follow STRONGER on Facebook , Twitter , Instagram and YouTube. And don’t forget…follow us in signing the Safety Promise. Follow us in supporting the science.

Sincerely,
Maria Thacker-Goethe
President and CEO
Georgia Bio | Center for Global Health Innovation
Atlanta, Georgia

Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community

By Sheran Brown • February 21, 2025
Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community

Bipartisan PBM Reform Back in Focus as House Committee Plans Hearing

By Sheran Brown • February 20, 2025
A renewed push for prescription drug cost reform is gaining momentum in Congress, with the House Energy and Commerce Committee's health subcommittee planning a hearing on pharmacy benefit manager (PBM) reform for late February. The hearing, to be led by Rep. Buddy Carter (R-Ga.), signals a revival of bipartisan efforts to regulate these pharmaceutical intermediaries. PBMs, which negotiate drug prices for insurers and employers, have become a focal point in the broader discussion of healthcare costs. A previous bipartisan agreement to regulate these entities was crafted by Carter and Rep. Diana DeGette (D-Colo.) in the last Congress, though it ultimately stalled when the larger spending bill it was attached to faced opposition. The reform efforts enjoy broad support from both parties and the president, making it one of the few areas with potential for bipartisan cooperation. However, new complications have emerged as Republicans consider using PBM regulations to generate savings for their broader policy agenda, potentially requiring up to $880 billion in cost reductions. The path forward remains uncertain, with ongoing debates about whether such reforms would qualify for budget reconciliation and whether using PBM regulations as a funding mechanism could derail bipartisan cooperation. Meanwhile, stakeholders continue to disagree on the impact of additional PBM regulation, with pharmaceutical companies arguing that PBMs inflate drug costs while PBMs contend that new regulations would increase prices.

Council on State Biotechnology Associations says NIH funds are a critical component of innovation ecosystem

By Sheran Brown • February 20, 2025
The Council of State Biotechnology Associations (CSBA) has issued a strong warning about proposed cuts to National Institutes of Health (NIH) funding, emphasizing the critical role these grants play in America's biotech innovation ecosystem. The statement, below , comes amid concerns over recent guidance that would reduce NIH funding to key research institutions. ----------------------- “Today, the US biotech industry employs nearly 2.3 million people across the US and is making positive contributions to economic impact and national security across all 50 states. In fact, for every dollar the National Institutes of Health (NIH) contributes to a successful drug, the private sector invests over $65, underscoring the agency’s unparalleled return on investment. As the associations representing the bioscience industry across the nation, the Council on State Biotechnology Associations (CSBA) is concerned by recent guidance that would cut funding provided by the NIH to universities, hospitals, and other institutions that perform critical early-stage research. NIH grant funds are a critical component of our innovation ecosystem. Grants for basic research are the spark that leads to university-driven discoveries, with public-private partnerships and tech transfers that bridge early-stage research to industry-sponsored drug development and ultimately to FDA approved medical advances for hundreds of diseases. While the administration looks for greater efficiency in the use of taxpayer dollars, it cannot be overstated - once scientific innovation moves abroad, it may never return. In the race for scientific innovation around the world, as our adversaries continue to increase government investments in research, we encourage President Trump to follow suit and ensure that we maintain our global leadership in an industry that was created and thrives across the US.”
MORE POSTS
Share by: